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ARTICLE OPEN
IGF-1R inhibition induces MEK phosphorylation
to promote survival in colon carcinomas
Qing Wang1, Yan Zhang1, Jiang Zhu1,2,5, Honggang Zheng3, Shuntai Chen3, Li Chen4 and Hsin-Sheng Yang1,4
The insulin-like growth factor 1 receptor (IGF-1R) governs several signaling pathways for cell proliferation, survival, and anti-
apoptosis. Thus, targeting IGF-1R appears as a reasonable rationale for tumor treatment. However, clinical studies showed that
inhibition of IGF-1R has very limited efficacy due to the development of resistance to IGF-1R blockade in tumor cells. Here, we
discovered that prolonged treatment of colon cancer cells with IGF-1R inhibitors (BMS-754807 and GSK1838705A) stimulates p70
KDa ribosomal protein S6 kinase 1 (p70S6K1) activation, a well-known kinase signaling for cell survival. We also found that p70S6K1
activation by IGF-1R inhibition is independent of K-Ras and PIK3CA mutations that frequently occur in colon cancer. Besides the
increased p70S6K1 phosphorylation, the phosphorylation of mitogen-activated protein kinase kinase 1 and 2 (MEK1/2) was
elevated in the cells treated with BMS-754807. Interestingly, the increases in MEK1/2 and p70S6K1 phosphorylation were also
observed when cells were subjected to the treatment of AKT inhibitor or genetic knockdown of AKT2 but not AKT1, suggesting that
AKT2 inhibition stimulates MEK1/2 phosphorylation to activate p70S6K1. Conversely, inhibition of MEK1/2 by MEK1/2 inhibitor
(U0126) or knockdown of MEK1 and MEK2 by corresponding mek1 and mek2 siRNA enhanced AKT phosphorylation, indicating
mutual inhibition between AKT and MEK. Furthermore, the combination of BMS-754807 and U0126 efficiently decreased the cell
viability and increased cleaved caspase 3 and apoptosis in vitro and in vivo. Our data suggest that the treatment of colon tumor
cells with IGF-1R inhibitors stimulates p70S6K1 activity via MEK1/2 to promote survival, providing a new strategy for colorectal
cancer therapeutics.
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INTRODUCTION
The insulin-like growth factor 1 receptor (IGF-1R) belongs to the
tyrosine kinase receptor family. By binding with IGF-1, IGF-2, and
insulin, IGF-1R activates downstream pathways including phos-
phoinositide 3 kinase (PI3K)/AKT and Ras/extracellular signal-
regulated protein kinase (ERK) pathways,1 two frequently
activated pathways in colorectal cancer. Elevation of IGF-1R
expression or activity is frequently found in many types of
cancer, which is associated with tumor cell proliferation, survival,
anti-apoptosis, and drug resistance.2 For example, IGF-1R-
mediated activation of AKT, in turn, phosphorylates and inhibits
pro-apoptotic proteins such as Bad and caspase 9 to promote
survival.3,4 In colorectal cancer, IGF-1R expression levels are
commonly elevated in cancerous tissues relative to adjacent
normal tissues.5 Most importantly, the elevation of IGF-1R
expression is associated with a worse prognosis in colorectal
cancer patients.6 Since the IGF-1R signaling pathway is critical
for the development, maintenance, and survival of cancers,
many small molecule compounds and antibodies targeting IGF-
1R have been developed. Unfortunately, these anti-IGF-1R
agents have very limited efficacy in clinical trials,7–9 suggesting
the existence of a mechanism to antagonize the IGF-1R
inhibition in cancer cells.
Previously, we found that prolonged treatment of colon cancer
cells with an IGF-1R inhibitor, OSI-906, induces p70S6K1 activa-
tion.10 The induction of p70S6K1 activation in colon cancer cells is
associated with resistance of IGF-1R inhibition since knockdown of
p70S6K1 or inhibition of p70S6K1 activity enhances the cell
sensitivity to IGF-1R inhibition. p70S6K1 is a serine/threonine
kinase, which is the key downstream point of the AKT-mTOR
pathway.11 p70S6K1 activation has been shown to boost cell
survival.11 The well-known mechanism for p70S6K1 to promote
survival is that p70S6K1 phosphorylates mouse double minute 2
(MDM2) leading to polyubiquitination and degradation of p53,
and thus represses p53-dependent apoptosis.12 Interestingly,
p70S6K1 is one of the downstream targets of AKT. Inhibition of
AKT activation by IGF-1R inhibitor, OSI-906, is supposed to
suppress p70S6K1 activation. However, colon tumor cells treated
with OSI-906 suppresses AKT activation but induces p70S6K1
phosphorylation.10 This finding raises the question of whether the
activation of p70S6K1 by OSI-906 is through IGF-1R inhibition or it
is a non-specific effect of OSI-906. If it is through IGF-1R inhibition,
what is the molecular mechanism to induce p70S6K1 activation?
We also discovered that the level of the tumor suppressor,
Programmed cell death 4 (Pdcd4), correlates with the chemosensi-
tivity to OSI-906 in colon tumor cells.10 Colon tumor cells with high
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Pdcd4 expression is sensitive to OSI-906 inhibition, while Pdcd4
knockdown gains the resistance to OSI-906 inhibition.10 Conversely,
colon cells with low Pdcd4 level are resistant to OSI-906 inhibition and
this resistance is relieved by Pdce4 overexpression.10 Pdcd4 has been
demonstrated to inhibit tumor promotion and progression,13 whose
expression is often downregulated in colorectal cancer.14,15 Pdcd4
physically interacts with eukaryotic initiation factor 4A (eIF4A) and
attenuates protein translation.16 eIF4A is an ATP-dependent RNA
helicase belonging to DEAD-box RNA helicase protein family.17 eIF4A
mutants that are defective in RNA helicase activity inhibits translation
of mRNAs with stable secondary structures more efficiently than less-
structured mRNAs,18 indicating that eIF4A’s helicase activity is
required for translation of structured mRNAs. Thus, inhibiting eIF4A
activity by Pdcd4 is expected to suppress protein translation,
especially the translation of structured mRNAs. This notion was
recently confirmed by identification of the Pdcd4 target, stress-
activated-protein kinase interacting protein 1 (Sin1), whose translation
is inhibited by Pdcd4 through suppressing eIF4A activity.19
In this study, we intend to resolve the mechanism of induction
of p70S6K activation by IGF-1R inhibition using a different IGF-1R
inhibitor, BMS-754807. BMS-754807 is a potent IGF-1R inhibitor,
which has been reported to have a limited off-target effect since
the transcriptional profile is similar between wild-type MEF cells
treated with BMS-754807 and IGF-1R null MEF cells.20,21 We found
that colon tumor cells treated with an IGF-1R inhibitor, BMS-
754807 or GSK1838705A, induced phosphorylation of p70S6K1 as
OSI-906 does. We also found that Pdcd4 inhibited the induction of
p70S6K1 phosphorylation by IGF-1R inhibitor was through
suppression of p70S6K1 translation. In addition, BMS-754807
treatment induced phosphorylation of mitogen-activated protein
kinase kinase 1 and 2 (MEK1/2), which contributed to BMS-
754807-induced p70S6K1 activation for survival in colon cancer
cells. These findings provide new mechanistic insights into
combating the resistance of IGF-1R inhibition.
RESULTS
Induction of p70S6K1 phosphorylation by IGF-1R inhibitor is
independent of K-Ras and PIK3CA mutations
Previously, we demonstrated that treatment of HCT116 and
SW480 cells with an IGF-1R inhibitor, OSI-906, increases phosphor-
ylation of p70S6K1.10 To test whether the induction of p70S6K1
phosphorylation is due to inhibition of IGF-1R signaling pathway
not non-specific outcome of OSI-906, the HCT116 cells were
treated with other IGF-1R inhibitors, BMS-754807 and
GSK1838705A, for 0–72 h. Since IGF-1R inhibition results in
suppression of downstream AKT activation, the IGF-1R inhibitors
(BMS-754807 and GSK1838705A) efficiently inhibit AKT phosphor-
ylation, indicating that the drugs function properly. Phosphoryla-
tion of p70S6K1 was significantly induced at 48 and 72 h in cells
treated with BMS-754807 or GSK1838705A (Fig. 1a, b). These
findings suggest that the induction of p70S6K1 phosphorylation is
Fig. 1 Induction of p70S6K1 phosphorylation by IGF-1R inhibitors. a, b IGF-1R inhibitors induced p70S6K1 phosphorylation in HCT116 cells.
Cells were treated with BMS-754807 (240 nM, BMS) or GSK1838705A (2 μM, GSK) for 0–72 h. a Representative western blot images are shown.
b Densitometric quantification of the western blot results in (a). For each inhibitor, the band intensity of p-p70S6K1/GAPDH with 0 h treatment
is designated as 1. Data from three independent experiments were analyzed by one-sample t-test (mean ± SD; *P < 0.05; **P < 0.01). c, d The
induction of p70S6K1 phosphorylation by IGF-1R inhibition is independent of K-Ras or PIK3CA mutations. Cells were treated with BMS-754807
(240 nM) for 0–72 h. c Representative western blot images are shown. d Densitometric quantification of western blot results in (c). The band
intensity of p-p70S6K1/GAPDH with 0 h treatment in each cell line is designated as 1. Data from three independent experiments were
analyzed by one-sample t-test (mean ± SD; *P < 0.05)
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through inhibition of IGF-1R. It has been reported that mutations
in K-Ras and PIK3CA frequently occur in colorectal cancer,
~35–45% and 20%, respectively.22,23 Since IGF-1R governs PI3K/
AKT and Ras/ERK signaling pathways,1 we next to test whether
induction of p70S6K1 phosphorylation is dependent on K-Ras or
PIK3CA mutation. Beside HCT116 cells (K-Ras mutant, PIK3CA
mutant),24 we treated SW480 (K-Ras mutant, PIK3CA WT),24 LoVo
(K-Ras mutant, PIK3CA WT),24 and RKO (K-Ras WT, PIK3CA
mutant)24 cells with BMS-754807 (240 nM) for 0–72 h. The
p70S6K1 phosphorylation was induced in all cells treated with
BMS-754807 for 48–72 h (Fig. 1c, d), indicating that induction of
p70S6K1 phosphorylation by inhibition of IGF-1R is independent
of K-Ras or PIK3CA mutations.
IGF-1R inhibition-induced p70S6K1 phosphorylation contributes to
cell survival
Previously, we showed that Pdcd4 suppresses IGF-1R inhibition-
induced p70S6K1 phosphorylation when cells were treated with
the IGF-1R inhibitor, OSI-906.10 To test whether downregulation of
Pdcd4 enhanced p70S6K1 phosphorylation by BMS-754807 to
promote cell survival, we treated Pdcd4 knockdown (HT29-P) and
LacZ shRNA transfected control (HT29-L) cells with BMS-754807 for
0–72 h. As expected, Pdcd4 knockdown cells (HT29-P) dramatically
induced p70S6K1 phosphorylation when cells were treated with
BMS-754807 for 24–72 h (Fig. 2a and Supplementary Fig. 1). As a
consequence, the phosphorylation of the p70S6K1 downstream
target, MDM2, also elevated with BMS-754807 treatment (Fig. 2a
and Supplementary Fig. 1). Consistent with the increase in survival
signal, i.e., phosphorylation of p70S6K1 and MDM2, the apoptotic
protein, cleaved caspase 3, significantly decreased in the HT29-P
cells comparing to that in the HT29-L cells (Fig. 2a, lanes 3 and 4 vs
lanes 7 and 8). To further confirm the inhibition of BMS-754807-
induced p70S6K1 activation leading to cell death, we treated
HCT116 cells with BMS-754807, PF-4708671 (p70S6K inhibitor), or
both. As shown in Fig. 2b, cells treated with both BMS-754807 and
PF-4708671 reversed the BMS-754807-induced phosphorylation of
MDM2 and increased the levels of cleaved caspase 3. Besides,
HCT116 cells treated with both BMS-754807 and PF-4708671
significantly decreased in proliferation (Fig. 2c) and the number of
colonies (Fig. 2d) comparing with vehicle control, BMS-754807, or
PF-4708671. These findings suggest that the induction of p70S6K1
phosphorylation is the key event for cell survival in BMS-754807
treatment. It is noteworthy that PF-4708671 can inhibit p70S6K1
as shown by the diminished phosphorylation of its downstream
Fig. 2 BMS-754807-induced p70S6K1 phosphorylation contributes to cell survival. a BMS-754807 induced p70S6K1 phosphorylation in Pdcd4
knockdown cells. Western blot analyses were performed using cell extracts from control (HT29-L) and Pdcd4 knockdown (HT29-P) cells treated
with BMS-754807 (240 nM) for 0–72 h. Representative images are shown. b A combination of BMS-754807 and PF-4708671 reversed the BMS-
754807-induced p70S6K1 activation and increased the cleaved caspase 3 level. Western blot analyses were performed using cell extracts from
cells treated with vehicle, BMS-754807 (240 nM), PF-4708671(10 μM), and BMS-754807 (240 nM)+PF-4708671 (10 μM) for 72 h. Representative
images are shown. c, d The combination of BMS-754807 and PF-4708671 inhibits the proliferation and colony formation. c HCT116 cells were
treated with vehicle, BMS-754807 (240 nM), PF-4708671 (10 μM), BMS-754807 (240 nM)+PF-4708671 (10 μM) for 0–5 days. Cell viability was
determined by XTT. The absorbance at day 0 is designated as 100%. Data from four replicates were analyzed one-way ANOVA with Dunnett’s
multiple comparison (mean ± SD; #P < 0.05; ##P < 0.01; ###P < 0.001). d Cells were treated with vehicle, BMS-754807 (240 nM), PF-4708671
(10 μM), or BMS-754807 (240 nM)+PF-708671 (10 μM) for 7 days. Data from three replicates were analyzed by one-way ANOVA with Dunnett’s
multiple comparison (mean ± SD; ##P < 0.01; ###P < 0.001). BMS: BMS-574807; PF: 4708671
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target, ribosomal protein S6, even though the level of p70S6K1
phosphorylation increased (Fig. 2b).25
Knockdown of Pdcd4 increases p70S6K1 translation
Besides the enhanced phosphorylation of p70S6K1 by Pdcd4
knockdown, we noticed that the protein level of p70S6K1 also
increased (Fig. 2a, lane 1 vs. 5 and Fig. 3a). Since Pdcd4 functions as
a protein translation inhibitor,13 it is possible that Pdcd4 knock-
down promotes p70S6K1 translation and thereby increases the
p70S6K1 protein level. To test it, a sucrose gradient fractionation
was performed to separate free RNAs, monosomes, and polysomes
(Fig. 3b). During protein translation, the actively translated mRNAs
associated with many ribosomes to form polysomes. Thus, mRNAs
distributed in the polysomal fractions are the ones actively
translated. After fractionation, the mRNAs in each polysomal
fraction (fractions #8–13) were purified and quantified with RT-
qPCR. As shown in Fig. 3c, knockdown of Pdcd4 increased the
p70S6K1 mRNA population in the polysomal fractions. Among
these polysomal fractions, the level of p70s6k1 mRNA significantly
increased in the fraction #9, #10, #11, and #13 of HT29-P cells as
compared to the corresponding fraction of HT29-L cells (Fig. 3c). By
contrast, the levels of p70s6k2 mRNAs in the polysomal fractions of
HT29-P cells were similar to those of the HT29-L cells or 30%
decrease in the fraction #10 (Fig. 3d). These results indicate that
Pdcd4 knockdown promotes p70S6K1 translation.
Inhibition of AKT induces MEK1/2 phosphorylation but not ERK1/2
phosphorylation
IGF-1R inhibition has been shown to inhibit PI3K/AKT and Ras/ERK
signaling pathways.26 However, previous studies showed that ERK
phosphorylation is barely suppressed in several colon tumor cell
lines treated with IGF-1R inhibitor, OSI-906.27 Thus, it is interesting
to examine the effect of BMS-754807 on ERK phosphorylation. As
shown in Fig. 4a, the BMS-754807 functioned properly because it
efficiently inhibited AKT phosphorylation at Ser473 in both
HCT116 and SW480 cells. However, 72-h treatment of BMS-
754807 in HCT116 and SW480 cells did not change the levels of
phosphorylation of ERK1/2, showing BMS-754807 not able to
suppress ERK1/2 activation (Fig. 4a, b). Surprisingly, the phosphor-
ylation of MEK1/2, the upstream regulator of ERK1/2, was induced
in HCT116 and SW480 cells treated with BMS-754807 for 48–72 h
(Fig. 4a, b). We also found that the phosphorylation of JNK and
p38, two stress-induced kinases, were barely detectable in the
HCT116 cells treated with BMS-754807 for 72 h (Supplementary
Fig. 3), suggesting that IGF-1R inhibition did not alter JNK and
p38 signaling pathways. Our results indicate that colon HCT116
and SW480 cells treated with BMS-754807 induces phosphoryla-
tion of MEK1/2 but not ERK1/2.
Since BMS-754807 efficiently inhibited AKT phosphorylation at
Ser473 (Fig. 4a), we assumed that MEK1/2 phosphorylation might
be induced by inhibition of AKT activation. To test it, we treated
Fig. 3 Knockdown of Pdcd4 enhances p70S6K1 translation. a p70S6K1 protein levels were increased in Pdcd4 knockdown cells. The level of
p70S6K1 in control (HT29-L) and Pdcd4 knockdown (HT29-P) cells at 0 h treatment in Fig. 2a was quantified. The band intensity of p70S6K1/
GAPDH in HT29-L cells is designated as 1. Data from three independent experiments were analyzed by one-sample t-test (mean ± SD; *P < 0.05).
b Polysomal profiles of HT29-L and HT29-P cells. Pdcd4 knockdown increases p70s6k1mRNA (c) but not p70s6k2mRNA (d) in polysomal fractions.
The cell lysates from HT29-L and HT29-P cells were subjected to sucrose gradient fractionation. After fractionation, the mRNAs in each fraction
were purified and quantified with RT-qPCR. RT-qPCR was performed with three replicates to determine the relative levels of p70S6K1 or p70S6K2
mRNA by comparison of p70S6K1 or p70S6K2 mRNA in each polysomal fraction to that in corresponding pooled free RNAs and proteins (FRP)
fraction, respectively. Data from two independent experiments were analyzed by two-sample t-test (mean ± SD; #P < 0.05; ##P < 0.01)
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HCT116 cells with AKT inhibitor, MK-2206 (0.5 μM), for 0–72 h. As
expected, the phosphorylation of AKT at Ser473 was barely
detectable after MK-2206 treatment (Fig. 4c). As the BMS-754807
treatment, cells treated with MK-2206 for 48 and 72 h increased
MEK1/2 phosphorylation ~3- to 4-fold but did not affect ERK
phosphorylation (Fig. 4c, d). In addition, the phosphorylation of
p70S6K1 significantly elevated by MK-2206 treatment for 48 and
72 h (Fig. 4c, d). To further confirm that AKT inactivation increased
MEK1/2 phosphorylation, we knocked down AKT1 and AKT2
expression by transfection of akt1 and akt2 siRNAs. As shown in
Fig. 4e, transfection of akt1 and akt2 siRNA into HCT116 cells
significantly reduced the expression of AKT1 and AKT2, respec-
tively. Interestingly, knockdown of AKT2 but not AKT1 increased
~3.5-fold of MEK1/2 phosphorylation compared with the
scrambled siRNA transfected cells (Fig. 4e, f). Taken together,
our findings (Fig. 4) suggested that inhibition of AKT2 increases
MEK1/2 phosphorylation in colon tumor cells.
Inhibition of MEK1/2 increases AKT phosphorylation
To test whether MEK inhibition can increase AKT phosphorylation
to activate AKT, we knocked down MEK1 and MEK2 expressions
with mek1 and mek2 siRNA, respectively. Phosphorylation of AKT
at Ser473 was induced two- to fourfold by knockdown of MEK1 or
MEK2 comparing to that in control cells (Fig. 5a, b). To verify the
above observation, cells were treated with MEK inhibitor, U0126
(0–10 μM) and subsequently assayed for the status of AKT
phosphorylation. AKT phosphorylation at Ser473 did not change
in cells treated with 1 μM of U0126 but dramatically increased
when cells were treated with 5 or 10 μM of U0126 (Fig. 5c, d).
However, AKT phosphorylation at Thr308 was not detectable in
HCT116 cells (data not shown). As expected, p70S6K1 phosphor-
ylation also increased in cells treated with 5 and 10 μM of U0126
(Fig. 5c, d). These findings suggest that downregulation or
inactivation of MEK activates AKT/p70S6K axis. Remarkably,
U0126 increased the phosphorylation of MEK1/2 but inhibited
ERK1/2 phosphorylation in HCT116 cells, suggesting that U0126
functioned properly. This phenomenon was also observed in
H1299, A549, and MCF7 cells treated with 10 µM of U0126 for
0–72 h (Supplementary Fig. 4). Thus, it is possible that U0126
inhibited MEK kinase activity but increased its phosphorylation as
seen in p70SK6 inhibitor, PF-4708671.25 Interestingly, the phos-
phorylation of ERK1/2 was inhibited by U0126 (Fig. 5c) but not IGF-
1R inhibitors (Fig. 4a and ref. 27). This discrepancy may be due to
the different mechanisms employed by different inhibitors to
inhibit MEK1/2 activity, which requires further investigations.
The combination of BMS-704807 and U0126 efficiently suppresses
the growth and induces cell death in colon tumor cells
Our results suggested that activation of MEK1/2 is a key event for the
induction of p70S6K1 phosphorylation in resistance to IGF-1R inhibition.
Fig. 4 Inhibition of AKT induces phosphorylation of MEK1/2 but not ERK1/2. a, b BMS-754807 induces MEK1/2 phosphorylation in colon
tumor cells. Western blot analyses of MEK1/2 and ERK1/2 phosphorylation using extracts from cells treated with BMS-754807 (240 nM) for
0–72 h. a Representative images are shown. b Densitometric quantification of the levels of phospho-MEK and phoshpo-ERK in (a). The ratio of
phospho-MEK/GAPDH or phospho-ERK/GAPDH in HCT116 or SW480 cells with 0 h treatment is designated as 1. Data from three independent
experiments were analyzed by one-sample t-test (mean ± SD; *P < 0.05; **P < 0.01). c, d The inhibition of AKT induces phosphorylation of
MEK1/2. Western blot analyses using extracts from cells treated with MK-2206 (0.5 μM) for 0–72 h. c Representative images are shown.
d Densitometric quantification of levels of phospho-p70S6K1, phospho-MEK1/2, and phoshpo-ERK1/2 in (c). The ratio of phospho-p70S6K1/
GAPDH, phospho-MEK/GAPDH, or phospho-ERK/GAPDH at 0 h treatment is designated as 1. Data from three independent experiments were
analyzed from by one-sample t-test (mean ± SD; *P < 0.05; **P < 0.01). e, f AKT2 knockdown increases MEK1/2 phosphorylation. HCT116 cells
were transfected with scrambled siRNA, akt1 siRNA, or akt2 siRNA. Forty-eight hours post transfection, cell lysates were assayed by western
blot. e Representative western blot images are shown. f Densitometric quantification of phospho-MEK1/2 levels in (e). The ratio of phospho-
MEK/GAPDH of transfection with scrambled siRNA is designated as 1. Data from three independent experiments were analyzed by one-
sample t-test (mean ± SD; *P < 0.05; n.s. no significance)
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We, next, examined whether inhibition of MEK1/2 leads to suppression
of IGF-1R inhibition-induced p70S6K1 activation and promotes cell
death. We treated HCT116 cells with vehicle (DMSO), BMS-754807
(240 nM), U0126 (5 μM), and BMS-754807 (240 nM)+U0126 (5 μM) for
3 days. As shown in Fig. 6a, b, HCT116 cells treated with BMS-754807
and U0126 induced p70S6K1 phosphorylation (lanes 2 and 3). The
induction of p70S6K1 phosphorylation was abolished when cells were
treated with both BMS-754807 and U0126 (Lane 4), indicating that
suppression of MEK1/2 abolishes BMS-754807-induced p70S6K1
phosphorylation. As a consequence of p70S6K1 inhibition, the
phosphorylation of MDM2 decreased and cleaved caspase 3 increased
(Fig. 6a, b). To further validate whether a combination of BMS-754807
and U0126 efficiently inhibits proliferation and induces cell death, we
performed cell growth and apoptosis assays. As shown in Fig. 6c, cells
treated with BMS-754807 or U0126 slightly inhibited cell growth. In
contrast, the cell growth was significantly inhibited with the
combination of BMS-754807 and U0126 comparing with vehicle
control, BMS-754807, or U0126 alone. Besides, the colony number also
significantly reduced in cells treated with BMS-754807+U0126
comparing to the vehicle, BMS-754807, or U0126 treated cells (Fig.
6d). Consistent with the growth inhibition, cell death significantly
increased in BMS-754807+U0126 treated cells than that in vehicle,
BMS-754807, or U0126 treated cells (Fig. 6e).
To confirm the results from cultured cells, we tested the efficacy
of the combination of BMS-754807 and U0126 on suppressing
tumor growth in HCT116 cells derived tumor xenograft. The
average tumor volume in mice treated with BMS-754807+ U0126
increased about twofold during the 12-day treatment while the
tumor volume increased about sevenfold in the vehicle-treated
mice (Fig. 7a). The average tumor volume in combination-treated
mice was ~50% of that in mice treated with BMS-754807 or U0126
alone (Fig. 7a). In consistent with the tumor volume, the average
tumor weight from the combination-treated mice was ~40% of
that in the mice treated with BMS-754807 or U0126 alone (Fig. 7b,
c). To verify that BMS-754807+ U0126 enhances apoptosis and
attenuates proliferation in vivo, the tumor tissue sections were
subjected to the analysis of proliferation and apoptosis by staining
with Ki-67 and TUNEL, respectively. As shown in Fig. 7d, the tumor
tissues from mice treated with BMS-754807+ U0126 showed the
least Ki-67 and the most TUNEL comparing to the tumors from the
mice treated with vehicle control, BMS-754807, or U0126. The Ki-
67 positive-staining cells in tumors from mice treated with BMS-
754807, U0126, and BMS-754807+ U0126 were ~60%, 63%, and
40% of those in tumors from vehicle-treated mice, respectively.
Conversely, the TUNEL positive-staining cells in tumors from BMS-
754807, U0126, and BMS-754807+ U0126 treated mice were ~7-
fold, 10-fold, and 19-fold higher than those from vehicle-treated
mice, respectively. These in vitro and in vivo findings (Figs. 6 and
7) suggest that inhibition of MEK1/2 suppresses IGF-1R-inhibition-
induced p70S6K1 activation in colon tumor cells, providing a new
strategy for colon cancer therapy.
DISCUSSION
In this study, we found that extensive treatment of IGF-1R inhibitor
induced phosphorylation of p70S6K1 in colon tumor cells (Fig. 1).
Inhibition of p70S6K by PF-4708671 or suppression of p70S6K1
translation by Pdcd4 significantly increased the efficacy of BMS-
754807 in promoting cell death and suppressing cell growth (Figs.
2 and 3). IGF-1R inhibitor elevated p70S6K1 phosphorylation, at
Fig. 5 Inactivation of MEK1 or MEK2 stimulates AKT phosphorylation. a, b Knockdown of MEK1 or MEK2 boosts AKT phosphorylation. Cells
were transfected with scrambled siRNA, mek1 siRNA, or mek2 siRNA. After 48 h, cell lysates were subjected to western blot analysis.
a Representative images are shown. b Densitometric quantification of phospho-AKT levels in (a). The ratio of phospho-AKT/GAPDH of
transfection with scrambled siRNA is designated as 1. Data from three independent experiments were analyzed by one-sample t-test (mean ±
SD; *P < 0.05). c, d Inhibition of MEK1/2 activation induces AKT phosphorylation. HCT116 cells were treated with 0, 1, 5, and 10 μM of U0126 for
72 h. The cell lysates were used to examine the levels of phospho-AKT. c Representative western blot images are shown. b Densitometric
quantification of phospho-AKT and phospho-p70S6K1 levels in (c). The ratio of phospho-AKT/GAPDH or phospho-p70S6K1 in cells with 0 μM
of U0126 is designated as 1. Data from three independent experiments were analyzed by one-sample t-test (mean ± SD; *P < 0.05; **P < 0.01)
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least in part, through activation of MEK1/2 (Figs. 4 and 5), and the
combination of the IGF-1R inhibitor and MEK inhibitor significantly
suppressed cell growth and induced cell death in both cultured
cells and mice (Figs. 6 and 7). Our findings provide a new
mechanistic insight into the resistance of IGF-1R inhibition in
which MEK1/2 activation stimulates the survival signal (Fig. 8).
p70S6K1 activation has been shown to enhance cell survival
and reduce apoptosis.28 For example, p70S6K1 phosphorylates
MDM2 at Ser166 resulting in polyubiquitination and degradation
of p53 and thereby inhibits p53-dependent apoptosis.12 Inhibition
of p70S6K1 results in the dephosphorylation of the pro-apoptotic
protein, Bad, leading to mitochondria-dependent apoptosis.29 The
finding that prolonged treatment with IGF-1R inhibitor induced
p70S6K1 phosphorylation suggests the importance of p70S6K1
phosphorylation in cell survival when IGF-1R is inhibited (Fig. 1). In
agreement with this scenario, inhibition of p70S6K1 activity by
p70S6K inhibitor, PF4708971, significantly increased the cell
sensitivity to IGF-1R inhibition via reducing the cell growth and
colony formation (Fig. 2). Besides the colon cancer cells, the
elevation of p70S6K1 phosphorylation is also observed in breast
cancer MCF7 cells treated with an IGF-1R inhibitor, OSI-906.30
Collectively, our findings indicate that enhancement of p70S6K1
phosphorylation is a key event for the resistance to IGF-1R
inhibition in colon cancer cells.
The result that Pdcd4 knockdown increased the distribution of
p70s6k1 mRNA but not p70S6K2 mRNA in the polysomal fractions
indicates Pdcd4 inhibiting p70S6K1 translation (Fig. 3). By binding
with eIF4A, Pdcd4 inhibits eIF4A RNA helicase activity and thereby
suppresses translation.16 During translation initiation, eIF4A’s
helicase activity is essential to unwind the structured mRNA at
5′untranslated region (5′UTR), which allows the translation
initiation complex moving from 5′ to 3′ direction to locate at
the AUG codon.17 Thus, inhibition of eIF4A helicase activity results
in suppression of translation, especially the translation of mRNAs
with stable secondary structures at 5′UTR. Pdcd4 was initially
demonstrated to preferentially inhibit translation of the luciferase
mRNA possessing an artificial stem-loop structure at 5′UTR with
the free energy of −44.8 kcal/mol.31 This concept was recently
confirmed by the identification of Sin1 as a Pdcd4 target, whose
mRNA forms a secondary structure at 5′UTR with the free energy
of −145 kcal/mol.19 In addition to inhibiting eIF4A activity, Pdcd4
may repress protein translation through binding with RNA by
preventing the formation of the translation initiation complex.32
Since the partial 5′UTR of p70S6K1 mRNA forms a secondary
structure with the free energy of −82.30 kcal/mol, it is most likely
that Pdcd4 inhibits the p70S6K1 translation via repressing eIF4A
activity. Yet, the mechanism needs to be further investigated.
Interestingly, it has been reported that Pdcd4 is phosphorylated at
Fig. 6 The combination of BMS-754807 and U0126 significantly inhibits the growth in colon tumor cells. a, b Inhibition of MEK1/2 suppresses
BMS-754807-induced p70S6K1 phosphorylation and increases cleaved caspase 3. Cells were treated with vehicle (DMSO), BMS-754807, U0126,
or BMS-754807+ U0126 for 72 h and subsequently used for western blot assays. a Representative images are shown. b Densitometric
quantification of levels of phospho-p70S6K1, phospho-MDM2, and cleaved caspase 3 in (a). The ratio of phospho-p-70S6K1/GAPDH, phospho-
MDM2/GAPDH or cleaved caspase 3/GAPDH in vehicle-treated cells is designated as 1. Data from three independent experiments were
analyzed by one-sample t-test (n= 3; mean ± SD; *P < 0.05; **P < 0.01) or two-sample t-test (mean ± SD; ##P < 0.01; ###P < 0.001). c Proliferation
assay. Cells were treated with indicated drugs for 0–5 days and the viability was measured with XTT. The absorbance at day 0 is designated as
100%. Data from four replicates were analyzed by one-way ANOVA with Dunnett’s multiple comparison (mean ± SD; #P < 0.05; ##P < 0.01;
###P < 0.001). d Clonogenic assay. Cells were treated with indicated drugs for 7 days. Data from three replicates were analyzed by one-way
ANOVA with Dunnett’s multiple comparison (mean ± SD; #P < 0.05; ##P < 0.01; ###P < 0.001). The representative images are shown at the right.
e Apoptosis assay. Cells were treated with the indicated drugs for 72 h, and the apoptotic cells were assessed using Annexin V assays. Data
from three replicates were analyzed by one-way ANOVA with Dunnett’s multiple comparison (mean ± SD; ###P < 0.001). The representative
images are shown at the right. BMS: BMS-754807
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Ser67 by p70S6K and followed by proteasomal degradation.33
Here, the result of Pdcd4 regulating p70S6K1 translation indicates
a feedback regulation between Pdcd4 and p70S6K1.
Our data showed that inhibition of MEK1/2 by a pharmacolo-
gical inhibitor (U0126) abolished the IGF-1R inhibition-induced
p70S6K1 phosphorylation (Fig. 6). Inhibition of MEK1/2 by U0126
or MEK1/2 knockdown results in increased phosphorylation of AKT
and p70S6K1 (Fig. 5). These findings indicate that the MEK1/2
activation is an essential event for p70S6K1 activation by IGF-1R
inhibition. Activation of IGF-1R leads to the stimulation of two
major downstream pathways, PI3K/AKT and Ras/ERK pathways.1
Previous studies have shown the crosstalk between Ras/ERK and
PI3K/AKT pathway and thus inhibition of one pathway may induce
activation of the other one.34 For example, in response to various
stimulations, AKT negatively regulates ERK activation through
inhibition of c-Raf phosphorylation.35,36 Conversely, inhibition of
AKT activity by MN-2206 upregulates EKR phosphorylation in
multiple myeloma cells.37 In agreement with this scenario, we
observed that inhibition of AKT by BMS-754807 or MN-2206
notably increased the phosphorylation of MEK1/2 (Fig. 4a–d).
Moreover, knockdown of AKT2 but not AKT1 significantly
increased MEK1/2 phosphorylation (Fig. 4e, f). These findings
indicate that the inactivation of AKT2 stimulates MEK1/2 activity in
colon cancer cells resistant to IGF-1R inhibition. Also, inactivation
of MEK1/2 by U0126 or knockdown of MEK1 or MEK2 increased
AKT phosphorylation (Fig. 5), suggesting that AKT and MEK
mutually repress each other. How does MEK activate AKT?
Previous studies have demonstrated that MEK inhibition stimu-
lates AKT activity through an ERK-mediated feedback loop
activation.37–39 Since colon cancer cells treated with IGF-1R
inhibitors do not change the ERK phosphorylation (Fig. 6a and
ref. 27), ERK does not likely play a role in AKT activation. A recent
study by Procaccia et al. suggested that AKT and MEK may directly
bind each other.40 It is necessary to further investigate whether
AKT and MEK bind each other to mutually suppress the
counterpart.
Taken together, our results revealed that inhibition of AKT leads
to activation of MEK1/2 to elevate p70S6K1 phosphorylation, while
suppression of MEK1/2 results in the enhancement of AKT
phosphorylation and thereby stimulation of p70S6K1 activity.
Thus, phosphorylation of MEK1/2 is critical for p70S6K1 activation
in colon cancer cells when IGF-1R is inhibited. Furthermore, a
combination of IGF-1R inhibitor (BMS-754807) and MEK inhibitor
(U0126) significantly suppressed cell viability and colony forma-
tion in cultured cells (Fig. 6) and tumor growth in mice (Fig. 7).
Therefore, our data also provide a promising strategy of
combining the IGF-1R and MEK1/2 inhibitors to suppress colon
tumor growth. It is noteworthy that our data suggested inhibition
Fig. 7 The combination of BMS-754807 and U0126 significantly suppresses tumor growth in the HCT116 colon xenograft model. NCr nude
mice (five mice per group) were treated with vehicle [10% (v/v) DMSO in corn oil], BMS-754807 (25mg/kg, BMS), U0126 (15mg/kg), or BMS-
754807+ U0126 (25mg/kg+15mg/kg) for 12 days. a The tumor volume was measured every other day with calipers. Data were analyzed by
one-way ANOVA with Dunnett’s multiple comparison versus vehicle, BMS-754807, or U0126 after 12-day treatment (mean ± SD; ###P < 0.001).
b Image of tumors after 12-day treatment. c The BMS-754807+U0126 treatment significantly lowered the average tumor weight comparing
to the vehicle, BMS-754807, or U0126 treatment. Data were analyzed by one-way ANOVA with Dunnett’s multiple comparison (mean ± SD;
##P < 0.01; ###P < 0.001). d Tumor sections were examined for proliferation (stained with Ki-67) and apoptosis (stained with TUNEL). The
representative images are shown; scale bar, 10 μm. e, f The number of positive-staining cells in tumors in each treatment was calculated as the
average number of four random images. The data were analyzed by one-way ANOVA with Dunnett’s multiple comparison (mean ± SD; ###P <
0.001). BMS: BMS-754807
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of both IGF-1R and MEK1/2 attenuated p70S6K1 activation to
promote cell death. Considering the complexity of crosstalk
between signaling pathways, an unknown p70S6K independent
mechanism might exist to promote cell survival, which is inhibited
by the combination of IGF-1R and MEK1/2 inhibitors. This
unknown mechanism needs further investigation.
MATERIALS AND METHODS
Reagents
BMS-754807, OSI-906, and GSK1838705A were obtained from
Chemie Tek. MK-2206 and PF-4708671 were purchased from
Selleckchem. U0126 was purchased from MedChemExpress. All
drugs were dissolved in DMSO at a proper concentration and
stored at −20 °C.
Cell lines and culture
The HT29, HCT116, SW480, and LoVo cells were purchased from
the ATCC and the RKO cell was a gift from Dr. Douglas Boyd (MD
Anderson Cancer Center, Houston, TX). HT29, HCT116, and RKO
cells were grown in McCoy’s medium (Invitrogen). LoVo and
SW480 cells were cultured in RPMI-1640 medium (Hyclone). HT29-
shLacZ (HT29-L) and HT29-shPdcd4 (HT29-P) cells were previously
generated.15 Cells were cultured in the medium with 10% FBS,
2 mM L-glutamine, and 100 U/mL penicillin–streptomycin and
incubated at 37 °C in a humidified atmosphere of 5% CO2 in air.
Cell proliferation and clonogenic assays
The TACS XTT cell proliferation assay kit (Trevigen) was used for
cell proliferation assays as described previously.41 Briefly, 5 × 103
cells/well were seeded onto a 96-well plate 1 day before drug
treatment. The sodium 3′-[1-(phenylaminocarbonyl)−3,4-tetrazo-
lium]-bis (4-methoxy-6-nitro) benzene sulfonic acid hydrate (XTT)
labeling mixture was added to the cell culture for 30min and
subsequently, the absorbance at 490 nm was measured using the
iMark microplate reader (Bio-Rad Laboratories). For clonogenic
assays, 1000 cells were seeded on a six-well plate and
subsequently treated with drugs for 7 days. The number of
colonies was determined after staining with 1% (w/v) crystal violet.
Apoptosis assays
The Annexin V–FITC Apoptosis Kit (Biolegend) was used for
apoptosis assays according to the manufacturer’s protocol. The
percentage of apoptotic cells was measured by a FacsCalibur cell
analyzer (BD Biosciences).
Western blot analysis
Cells were lysed in lysis buffer [50 mM Tris-HCl (pH 7.5), 1% NP-40,
0.5% (v/v) sodium deoxycholate, 150mM NaCl and 1× Halt
protease and phosphatase inhibitor mixture (Pierce)] on ice for
1 h. Twenty to forty microgram of protein was separated onto
4–12% SurePAGE gel (Genscript) and transferred to nitrocellulose
membrane. After incubation with primary antibodies followed by
horseradish peroxidase-linked secondary antibody, the target
protein was visualized by Immobilon Western Chemiluminescent
HRP substrates (Millipore). The antibodies against phospho-AKT
(Ser473) (4060), AKT(pan) (4691), phospho-p70S6K(Thr389) (9205),
p70S6K (2708), phospho-ERK1/2(Thr202/Tyr204) (4370), ERK1/2
(4695), phospho-S6 ribosomal protein (Ser235/236) (4858), S6
ribosomal protein (2217), phospho-MDM2(Ser166) (3521), phos-
pho-MEK1/2(Ser217/221) (9154), MEK1/2 (8727), MEK1 (12671),
and cleaved caspase 3 (9664) were purchased from Cell Signaling
(1:1000 or 1:2000 dilution). The MEK2 (67410–1-Ig) antibody was
purchased from Proteintech (1:4,000 dilution). The GAPDH (sc-
47724) antibody was purchased from Santa Cruz Biotechnology
(1:5000 dilution).
Sucrose gradient fractionation and polysome analysis
Sucrose gradient fractionation was carried out as described
previously.19 Briefly, cycloheximide (10 μg/ml) was added into
the culture medium and incubated for 10min before cells were
harvested. The cells were lysed in lysis buffer [10 mM Tris (pH 7.4),
10 mM KCl, 2 mM MgCl, 1 mM EGTA, 1 mM DTT, 0.05% (v/v) Triton
X-100 and 1× protease inhibitor (Pierce)] for 30 min on ice. After
centrifugation, the protein concentration of the supernatant was
determined. An equal amount of protein in the supernatant was
layered onto 10–45% (w/w) sucrose gradient and centrifuged at
36000 r.p.m. for 2 h to separated free RNAs and ribosome-bound
RNAs. Fractions were collected using Piston Gradient Fractionator
(Biocomp) and Econo UV monitor (Bio-Rad). Data were acquired
by Gradient Profiler software (Biocomp).
RNA extraction and RT-qPCR
Total RNA was extracted from each sucrose gradient fraction using
Trizol reagent (Invitrogen). The first strand of cDNA was synthesized
from each fraction using the Superscript First-Strand Synthesis
System (ThermoFisher). The p70S6K1, p70S6K2, and GAPDH mRNA
levels were quantified by qPCR using primers purchased from
Qiagen. The relative p70S6K1 or p70S6K2 mRNA levels were
calculated by the 2−ΔΔCt method.42 The average Ct values of three
replicates in each fraction for p70S6K1 or p70S6K2 mRNA was
normalized to the average Ct value of internal control GAPDHmRNA
using the formula ΔCt= Ct(p70S6K1)-Ct(GAPDH). The relative level
of p70S6K1 or p70S6K2 mRNA was determined by comparison of
p70S6K1 or p70S6K2 mRNA in each polysomal fraction to that in
the corresponding free RNAs fraction, respectively, using the
formula 2−[ΔCt(polysomal fraction)−ΔCt(free RNAs fraction)].
Knockdown of AKT and MEK
Cells (3.5 × 105) were transfected with 110 pmol of akt1, akt2,
mek1, or mek2 DsiRNA (Integrated DNA Technologies) using
INTERFERin in vitro siRNA transfection reagent (Polyplus) as
instructed by the manufacturer’s protocol. After 48 h, cells were
harvested for proliferation and Western blot analyses.
In vivo xenograft study
Male and female athymic nude mice (CrTac:NCr-Foxn1nu) were
purchased from Taconic at age of 4- to 5-week. The mice were
Fig. 8 Schematic diagram showing that IGF-1R inhibition induces
p70S6K1 activation to promote cell survival. Suppression of AKT
activation by IGF-1R inhibitors (OSI-906, BMS-754807, and
GSK1838705A) or AKT inhibitor (MK-2206) results in stimulation of
MEK1/2 activity. Since AKT and MEK1/2 mutually repress each other,
the inactivation of MEK1/2 activates AKT, which may lead to
p70S6K1 phosphorylation to enhance cell survival. While activation
of MEK1/2 represses AKT, but still increases p70S6K1 phosphoryla-
tion through an unknown mechanism. In addition, inhibition of
p70S6K1 activation by PF-4708671 or Pdcd4 overcomes the BMS-
754807-induced p70S6K1 activation and thus reduces cell survival
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housed under pathogen-free conditions with commercial diet,
water ad libitum, and 12 h light/12 h dark cycle. The experimental
protocol was approved by IACUC of the University of Kentucky
based on the NIH guidelines. Two million HCT116 cells were
injected s.c. into the flank of each mouse and the tumor size was
monitored and determined as previously described.10 When
tumors reached 50–150mm3, mice were randomly divided into
four groups (five mice per group) and i.p. injected with (i) vehicle
[10% (v/v) DMSO in corn oil); (ii) BMS-754807 (25 mg/kg); (iii)
U0126 (15 mg/kg); and (iv) BMS-754807 (25 mg/kg)+ U0126
(15 mg/kg) every day for 12 days. All mice under these treatments
showed no sign of toxicity, i.e., bodyweight loss more than 15%,
diarrhea, or decreased food intake.
Statistical analysis
Statistical analyses were performed using the one-sample t-test for
quantification of the band intensity of western blots, the two-
sample t-test for comparing the means of two groups, and the
one-way ANOVA with Dunnett’s multiple comparison for compar-
ing means among multiple groups. Data are shown as the mean ±
standard deviation (SD). The difference is considered statistically
significant at the P < 0.05 level.
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